Share Data

Industry Biopharmaceutical
Sector New drug discovery
Fiscal year end September 30
Shares issued and outstanding 42,172,0901*
Stock purchase warrants 1,609,309**
Stock options 5,137,655**
Fully diluted 48,919,054**
Cash ~$24.8 million**
Debt Nil**
Trading symbol AVXL
52-week range $2.43 – $6.64*
Financial statements and filings Anavex’s filings can be found on EDGAR.
Investor relations (866) 505-2895 – Toll free in North America
+1 (416) 489 0092 – Outside North America
ir@anavex.com
Transfer agent Nevada Agency and Trust
50 West Liberty Street, Suite 880
Reno, Nevada 89501
Tel: (775) 322-0626
Fax: (775) 322-5623
Transfer agent email: info@natco.org
Resident Agent email: corpserve@natco.org
Web site: www.natco.org

*  As at August 7, 2017
**As at June 30, 2017

Forms – Reverse Stock Split

Internal Revenue Service (United States) – Form 8937.

Form_8937_(signed)